Celgene Corp. (NASDAQ: CELG ) – This company is considered by S&P to have
"the brightest growth prospects among large-cap biotech companies." Its
impressive performance was led by its cancer products Revlimid and Vidaza. The
company also has a number of other products in the pipeline awaiting FDA
approval. Earnings are expected to reach $3.20 in 2011 and $3.80 in 2012, and
gross margins are expected to maintain 93%. Analysts target the stock at $75 to
$85 within 12 months.
No comments:
Post a Comment